Results 81 to 90 of about 88,244 (379)

NIR Ratiometric Fluorescent Antibody‐Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring

open access: yesAdvanced Science, EarlyView.
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li   +8 more
wiley   +1 more source

Synthesis, characterization and 11C radiolabeling of aminophenyl benzothiazoles:structural effects on the alkylation of amino group [PDF]

open access: yes, 2014
Several aminophenyl benzothiazoles were prepared with a view to using them as amyloid binding agents for imaging β-amyloid in Alzheimer's disease. These precursors were radiolabeled with 11C-positron-emitting radioisotope using an automated synthesizer ...
Bhalla, R.   +4 more
core   +1 more source

The Different Strategies for the Radiolabeling of [211At]-Astatinated Radiopharmaceuticals

open access: yesPharmaceutics
Astatine-211 (211At) has emerged as a promising radionuclide for targeted alpha therapy of cancer by virtue of its favorable nuclear properties. However, the limited in vivo stability of 211At-labeled radiopharmaceuticals remains a major challenge.
Jie Gao   +6 more
doaj   +1 more source

Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI

open access: yesNanomaterials, 2023
During the last decades, the utilization of imaging modalities such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance imaging (MRI) in every day clinical practice has enabled clinicians to ...
Maria-Argyro Karageorgou   +3 more
doaj   +1 more source

Radiolabeled antibody therapy

open access: yesSeminars in Oncology Nursing, 1987
Summary To summarize, radiolabeled antibodies are used as an experimental therapy to treat certain tumors that have tumor-associated antigens. Preliminary phase I–II studies have shown that radiolabeled antibodies did bring about a remission in some individuals while also avoiding many side effects.
openaire   +2 more sources

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

open access: yesAdvanced Science, EarlyView.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

Specific binding of radiolabeled Cry1Fa insecticidal protein from Bacillus thuringiensis to midgut sites in lepidopteran species [PDF]

open access: yes, 2012
Cry1Fa insecticidal protein was successfully radiolabeled with 125I-Na. Specific binding to brush border membrane vesicles was shown for the lepidopteran species Ostrinia nubilalis, Spodoptera frugiperda, Spodoptera exigua, Helicoverpa armigera ...
Ferré J   +4 more
core   +2 more sources

Novel radiolabeled antibody conjugates [PDF]

open access: yesOncogene, 2007
This article reviews the development of radioimmunoconjugates as a new class of cancer therapeutics. Numerous conjugates involving different antigen targets, antibody forms, radionuclides and methods of radiochemistry have been studied in the half-century since radioactive antibodies were first used in model systems to selectively target radiation to ...
D M, Goldenberg, R M, Sharkey
openaire   +2 more sources

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao   +14 more
wiley   +1 more source

Downregulation of Tumor Necrosis Factor Expression in the Human Mono-Mac-6 Cell Line [PDF]

open access: yes, 1989
Mono-Mac-6 cells, but not U937 cells, can be Induced to rapidly express tumor necrosis factor (TNF) mRNA and protein when triggered with Ilpopolysaccharlde (LPS) at 1 pg/mI. Preincubatlon of the cells for 3 d with low amounts of LPS (10 ng/mI) results In
Blömer, Kathi   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy